Induction Treatment
The details of treatment protocol were published.1During induction therapy, patients received ATRA at
25mg/(m2·d) as soon as morphology diagnosis of APL was
made. Mitoxantrone (MA) was administrated on day 3
(10mg/m2) or day 2-4 (7mg/ (m2·d) of
ATRA treatment for NHR or high risk (HR) patients (diagnostic WBC count
>10 × 109/L) respectively. Once the
diagnosis was genetically confirmed (5-6 days later), the patients were
randomized to ATO or RIF group. ATO was administrated at 0.16mg/(kg·d)
(≯10 mg/day) intravenously over 12 hours daily, while RIF was given at
135mg/(kg·d) (≯30 pills/day) orally three times daily, until complete
remission was achieved.
When WBC exceeded 10×109/L at the beginning of or
during induction treatment, hydroxyurea was administrated at
100mg/(kg·d). Dexamethasone at 0.3 mg/(kg·d) was given if
differentiation syndrome or ATRA-associated pseudotumor cerebri was
suspected. Transfusions of platelet, and fresh-frozen plasma,
cryoprecipitate and/or human fibrinogen (Fbg), were given for the aims
of maintaining platelet counts (PLT) greater than 30 ×
109/L, and Fbg greater than 1.5g/L, respectively. The
use of heparin or low-molecular weight heparins for management of
coagulopathy depended on doctors’ clinical judgment.